15+ Years of Biosimilar Experience in Europe: Omnitrope Case Study
Biosimilar competition can play a crucial role in the overall economic sustainability of the healthcare system. Biosimilars hold the potential to improve patient access to biologic therapies, balance spending, and unlock savings for innovation. IQVIA Institute has previously published reports on biosimilar sustainability (Advancing Biosimilar Sustainability, 2018, and Spotlight on Biosimilars, 2021).
This new report continues the conversation by assessing the status of biosimilar use in selected European countries and, in particular, by analyzing the value provided by the first biosimilar launched in Europe — Omnitrope®. This utilization of Omnitrope and the savings associated with it are assessed using proprietary IQVIA data for selected European countries. With more than 15 years since its approval, Omnitrope’s value to the overall health system is important to understand and can provide lessons for ensuring that future biosimilars are optimally utilized.